The Eye Roll in the Consult Room: When Your Oncologist Dismisses Your Integrative Plan
There is a particular kind of heartbreak that happens in cancer care that almost no one talks about.
It is the moment a patient begins to feel hope again. Not false hope. Not magical thinking. Real hope. The kind that comes when they realise they are not powerless. The kind that comes when they start reading, learning, walking, changing their food, sleeping better, regulating their stress, asking smarter questions, looking into acupuncture, exercise, hyperthermia, hyperbaric oxygen, nutraceuticals, repurposed medicines, and all the other ways they might support their body alongside conventional care. It is the moment they stop being a passive recipient of treatment and start becoming an active participant in their own healing.
And then they sit in front of an oncologist and hear one of the usual lines.
“If it worked, we’d be using it.”
“There’s no evidence for that.”
“None of that stuff works.”
“You can eat whatever you want.”
And just like that, the air goes out of them.
The motivation collapses. The confidence shrinks. The questions go back underground. The patient starts to wonder whether they are being foolish, desperate, gullible, difficult, or unrealistic. They feel subtly shamed for caring deeply about their own outcome. They feel talked down to for wanting to do more than just turn up for the next infusion. And what makes it worse is that these moments often happen when the patient is trying to reclaim agency in one of the most powerless seasons of their life.
That matters.
Because when a patient is told, in effect, that nothing they do outside standard oncology could possibly matter, what they hear is not just a medical opinion. What they hear is: sit down, be quiet, and let the system handle it. And for many people, that is not only disempowering — it is also not fully true.
Let me be clear from the start: I am not talking about rejecting oncology. I am not talking about abandoning chemotherapy, immunotherapy, radiation, surgery, or targeted treatment in favour of fantasy. I am talking about complementary medicine, not alternative medicine. I am talking about adding evidence-informed, terrain-focused support around conventional care. The National Cancer Institute makes this distinction clearly: complementary approaches are used alongside standard treatment; alternative approaches are used instead of it. Integrative medicine is the coordinated use of conventional treatment with complementary therapies that have some good-quality evidence for safety and usefulness.
That distinction is everything.
Because the question most patients are really asking is not: Can broccoli replace chemotherapy? or Can meditation shrink a tumour the way a targeted drug can? The question is much more intelligent than that. It is: What else can I do to improve the environment in which this cancer exists, to improve how I respond to treatment, to improve how I tolerate treatment, to reduce the biological factors that feed disease, and to improve the odds that my body does better than expected?
That is not quackery. That is mature medicine.
One of the problems in these conversations is that many oncologists compare integrative interventions to their own treatments in the wrong way. They ask, implicitly or explicitly, Does this work like chemotherapy? Does this kill cancer cells like radiation? Does this do what immunotherapy does? And when the answer is no, they dismiss it as irrelevant.
But most integrative interventions are not trying to be chemotherapy.
They are not designed to be direct stand-alone replacements for cytotoxic drugs. They work more indirectly than that. They change the terrain. They influence inflammation, insulin signalling, muscle mass, metabolic health, treatment tolerance, symptom burden, sleep, distress, fatigue, immune resilience, and the physiological conditions in which cancer either struggles more or thrives more easily. They support the body that is receiving treatment. They support the biology that surrounds the tumour. And in many cases, that matters enormously.
That is why the dismissive one-liners are so frustrating. They often reveal not a deep command of the evidence, but a very narrow understanding of what healing actually involves.
Because here is the truth: there is evidence for many of these things.
Not for all of them equally.
Not for all cancers equally.
Not in the simplistic “this cures cancer” way people sometimes want.
But real evidence nonetheless.
Take exercise, for example. Exercise is no longer a soft, optional lifestyle suggestion in oncology. It is one of the most evidence-backed supportive interventions we have. Current cancer fatigue guidelines recommend exercise during and after treatment because it reduces fatigue severity. They also recommend cognitive behavioural therapy, mindfulness-based programs, and tai chi or qigong in selected settings.
And exercise is not only about feeling better. It has now shown outcome-level benefit in at least some settings. In a major 2025 trial in colon cancer, a structured three-year exercise program started after adjuvant chemotherapy improved disease-free survival. At five years, 80% of the exercise group were disease-free compared with 74% of the education-only group. Studies across cancer survivors more broadly have also linked higher post-diagnosis physical activity with more than 30% lower cancer-specific and all-cause mortality in some analyses.
So when a patient is told that movement, fitness, and physical conditioning do not matter, that is not evidence-based caution. That is ignorance of one of the most powerful tools we have for improving outcomes and quality of life.
Then there is mind-body medicine. Patients are sometimes made to feel as though stress regulation, mindfulness, breathwork, yoga, or psychological work are just “nice extras” for the emotionally inclined. But this is not about incense and wishful thinking. Major oncology guidelines recommend mindfulness-based interventions for anxiety and depression in adults with cancer, and recommend mindfulness-based programs and CBT for fatigue after treatment. This does not mean mindfulness cures cancer. It means that calming the nervous system, improving coping, reducing distress, and supporting emotional regulation are legitimate parts of cancer care. That matters because a dysregulated, exhausted, terrified human being does not make the same decisions, tolerate the same treatments, or live in the same biology as someone who is more supported and internally steadier.
The same is true for acupuncture and selected supportive therapies. This is another category that gets dismissed with astonishing confidence by people who clearly have not looked at the literature. Integrative oncology pain guidelines now recommend acupuncture in selected pain settings, and allow for acupressure or reflexology in some contexts. Acupuncture is also used widely for side effects and symptom control. Again, this is not being positioned as a replacement for systemic therapy. It is being positioned as a supportive modality that can help the patient function better, suffer less, and stay more engaged with care.
And then there is nutrition and metabolic terrain.
This is one of the places patients feel most dismissed. “You can eat whatever you want” may sound liberating, but often it lands as abandonment. Patients instinctively understand that biology matters. They understand that blood sugar, muscle wasting, inflammation, obesity, treatment-related malnutrition, insulin resistance, and cachexia are not imaginary. Cancer nutrition guidelines are very clear that nutritional care matters, especially in preserving body composition, treatment tolerance, and recovery. That does not mean there is one perfect anti-cancer diet. It does mean it is absurd to act as though nutrition has no relevance just because it is not a chemotherapy drug.
Nutraceuticals also belong here, though they require discernment. This is where the conversation often gets messy because some people overstate what supplements can do, and some oncologists respond by dismissing all of them at once. Both extremes are lazy.
The adult version of the conversation is this: some natural compounds have meaningful supportive evidence in cancer care, especially around symptoms, weight loss, cachexia, and side effects. Ginger, for example, has evidence supporting a role alongside standard anti-nausea medication in chemotherapy-induced nausea and vomiting. Omega-3 fatty acids have been studied in cancer cachexia and remain part of the nutritional conversation, even though the evidence is mixed and not universally definitive. American ginseng may be recommended in some fatigue settings. None of this means every supplement works. It means the category is not empty, and it certainly is not reasonable to dismiss it wholesale.
Then we come to repurposed medicines — another area often dismissed with the wave of a hand. Drug repurposing in oncology is not a fringe fantasy; it is a real research field. There are systematic reviews of randomised trials and large reviews in major journals exploring how existing non-cancer medicines may affect tumour cells and the tumour microenvironment. Now, this is where honesty matters: the evidence is mixed. Some drugs that looked promising in observational data have not delivered in large definitive trials. Others remain intriguing but not proven. That does not mean the whole field is nonsense. It means it should be approached with discipline, tumour-specific judgment, and humility — not with the same kind of overclaiming that patients are rightly warned about elsewhere.
Hyperthermia is another example. Some oncologists still talk about it as though it were fringe. Yet the National Cancer Institute states clearly that hyperthermia can help other cancer treatments, including chemotherapy and radiation, work better. The limitations are also clear: it requires expertise and equipment, and it is not yet proven to help everyone live longer. But again, that is very different from saying it is nonsense.
Hyperbaric oxygen therapy is another area where the conversation needs to be more nuanced. It is not a proven stand-alone cancer treatment. But it does have meaningful evidence in the management of late radiation tissue injury, where it can improve oxygenation and healing in damaged tissues, and current reviews do not show that it stimulates tumour growth or increases recurrence risk. So again, if an oncologist says, “That has no role in cancer care,” that is simply too crude to be accurate.
This is what patients need to understand: integrative interventions do not have to mimic chemotherapy to matter.
That is the trap.
If you only respect interventions that kill cells directly in the way a drug does, you will miss a huge part of what shapes outcome. You will miss treatment tolerance. You will miss body composition. You will miss fatigue. You will miss inflammation. You will miss sleep. You will miss mood. You will miss insulin signalling. You will miss the patient’s ability to keep walking, eating, thinking clearly, sleeping, coping, staying strong enough for more treatment, and recovering enough to have a life afterwards.
And when you miss all that, you are not practising whole-person cancer care. You are practising tumour care.
Patients know this instinctively. That is why they go looking.
So what should a patient do when they walk into a consult feeling motivated and leave feeling shut down?
First, do not let a dismissive one-liner become the final word on your own body.
Second, separate the useful caution from the lazy dismissal. There are legitimate concerns about interactions, poor-quality products, and exaggerated claims. Those deserve respect. But “there’s no evidence for any of it” is often just not true. A better question is:
Which specific interventions concern you, and why?
Are you worried about interactions? About safety? About lack of efficacy? About timing?
That is a very different conversation.
Third, remember that your oncologist is an expert in oncology — not necessarily in nutrition, behavioural medicine, acupuncture, exercise physiology, hyperbaric medicine, hyperthermia, psychoneuroimmunology, or the wider world of integrative supportive care. That is not an insult. It is just a scope issue. You are allowed to build a team.
And finally, hold onto this: you likely have more influence than you are being told.
Not total control.
Not guarantees.
Not magical immunity from suffering.
But real influence.
Influence over how you sleep.
How you eat.
How you move.
How much muscle you keep.
How much inflammation you carry.
How you tolerate treatment.
How you recover.
How much distress rules your days.
How active a participant you are in your own healing.
That matters. Sometimes a great deal.
So no — you do not need to feel ashamed because you want to support your body beyond standard care.
No — you are not foolish for wanting more than the narrowest reading of the evidence.
And no — the fact that an oncologist has heard too many bad supplement stories does not mean your whole integrative plan is nonsense.
It means you need discernment.
It means you need strategy.
It means you need a team that can hold both science and possibility without collapsing into dogma.
Because the point of integrative oncology is not to reject medicine.
It is not anti-oncology…. It is oncology optimization.
Medical Disclaimer
The information provided in this article is for educational and informational purposes only and is not intended as medical advice. It should not be used as a substitute for professional medical consultation, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider before making any decisions about your cancer treatment, including dietary changes, metabolic strategies, repurposed medications, or integrative therapies.
Every individual’s medical condition is unique, and what works for one person may not be appropriate for another. Integrating metabolic and conventional oncology approaches should be done under the supervision of a highly experienced health professional who understands the complexity of cancer care and the potential interactions between different treatments.
No guarantees of outcome are expressed or implied, and reliance on any information provided in this article is at your own discretion and risk.
References
National Cancer Institute (NCI). Complementary, Alternative, or Integrative Health: What’s In a Name?
Available at: https://www.cancer.gov/about-cancer/treatment/cam/patientLyman GH, Greenlee H, Bohlke K, et al. Integrative therapies during and after breast cancer treatment: ASCO endorsement of the Society for Integrative Oncology clinical practice guideline. Journal of Clinical Oncology. 2018;36(25):2647–2655.
Carlson LE, Ismaila N, Addington EL, et al. Integrative Oncology Care of Symptoms of Anxiety and Depression in Adults With Cancer: Society for Integrative Oncology-ASCO Guideline. Journal of Clinical Oncology. 2023;41(28):4562–4591.
Mao JJ, Ismaila N, Bao T, et al. Integrative Medicine for Pain Management in Oncology: Society for Integrative Oncology-ASCO Guideline. Journal of Clinical Oncology. 2022;40(34):3998–4024.
Bower JE, Stan D, Bao T, et al. Management of Fatigue in Adult Survivors of Cancer: ASCO-Society for Integrative Oncology Guideline Update. Journal of Clinical Oncology. 2024.
National Cancer Institute (NCI). Hyperthermia to Treat Cancer.
Available at: https://www.cancer.gov/about-cancer/treatment/types/hyperthermiaBrown JC, Huedo-Medina TB, Pescatello LS, et al. Efficacy of exercise interventions in modulating cancer-related fatigue among adult cancer survivors: a meta-analysis. Cancer Epidemiology, Biomarkers & Prevention. 2011;20(1):123–133.
Patel AV, Friedenreich CM, Moore SC, et al. American College of Sports Medicine roundtable report on physical activity, sedentary behavior, and cancer prevention and control. Medicine & Science in Sports & Exercise. 2019;51(11):2391–2402.
Courneya KS, Booth CM, Gill S, et al. Effects of exercise on disease-free survival in patients with colon cancer: a randomized controlled trial. New England Journal of Medicine. 2025.
Rock CL, Thomson C, Gansler T, et al. American Cancer Society guideline for diet and physical activity for cancer prevention. CA: A Cancer Journal for Clinicians. 2020;70(4):245–271.
Arends J, Bachmann P, Baracos V, et al. ESPEN guidelines on nutrition in cancer patients. Clinical Nutrition. 2017;36(1):11–48.
Winkler G, Pál B, Nagybegányi E, et al. Effectiveness of benfotiamine in diabetic neuropathy. Diabetes Care. 1999;22(8):1296–1301.
(Relevant as mechanistic/neuropathy support rather than direct oncology evidence.)Hammes HP, Du X, Edelstein D, et al. Benfotiamine blocks pathways of hyperglycaemic damage. Nature Medicine. 2003;9(3):294–299.
(Relevant mechanistic support for advanced glycation end-products and nerve injury.)Skaper SD, Facci L, Fusco M, et al. Palmitoylethanolamide, a naturally occurring disease-modifying agent in neuropathic pain. CNS & Neurological Disorders - Drug Targets. 2014;13(1):46–54.
Costa B, Comelli F, Bettoni I, et al. The endogenous fatty acid amide palmitoylethanolamide protects from paclitaxel-induced neuropathic pain. Pain. 2008;139(3):541–550.
Wallimann T, Tokarska-Schlattner M, Neumann D, et al. The creatine kinase system and pleiotropic effects of creatine. Amino Acids. 2011;40(5):1271–1296.
Hershman DL, Unger JM, Crew KD, et al. Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for prevention of taxane-induced neuropathy. Journal of Clinical Oncology. 2013;31(20):2627–2633.
(Important as a cautionary reference; prevention results were not beneficial in this setting.)Ioakeim-Skoufa I, Papatheodorou E, Gavriilaki E, et al. Drug repurposing in oncology: a systematic review of randomized controlled clinical trials. Cancers (Basel). 2023;15(11):2972.
Goodwin PJ, Ligibel JA, Stambolic V. Metformin in breast cancer: time to move on? Journal of Clinical Oncology. 2022.
(With reference to the MA.32 trial showing no significant benefit in invasive disease-free survival.)Goodwin PJ, Parulekar WR, Gelmon KA, et al. Effect of metformin vs placebo on invasive disease-free survival in patients with breast cancer: the MA.32 randomized clinical trial. JAMA. 2022;327(20):1963–1973.
Dejonckheere CS, Spaander MCW, Delacroix V, et al. Hyperbaric oxygen therapy for chronic radiotherapy-related complications: a systematic review. Clinical and Translational Radiation Oncology. 2025.
Demir KC, Buehler M, Wenz F, et al. Hyperbaric oxygen therapy for managing cancer treatment complications: evidence and safety considerations. Frontiers in Oncology. 2025.
(Includes discussion that no evidence was found to suggest HBOT promotes tumour progression or recurrence.)Grassi L, Caruso R, Hammelef K, et al. Anxiety and depression in adult cancer patients: ESMO Clinical Practice Guideline. Annals of Oncology. 2023;34(10):913–930.
Deng GE, Rausch SM, Jones LW, et al. Complementary therapies and integrative medicine in oncology: patient use and clinician communication challenges. Journal of the National Comprehensive Cancer Network. 2013;11(4):437–447.
National Cancer Institute (NCI). Acupuncture (PDQ®)–Health Professional Version.
Available at: https://www.cancer.gov/about-cancer/treatment/cam/hp/acupuncture-pdqNational Cancer Institute (NCI). Curcumin (PDQ®)–Health Professional Version.
Available at: https://www.cancer.gov/about-cancer/treatment/cam/hp/curcumin-pdq